A phase Ia/IIb trial of the CXCR4 inhibitor X4P-001 and nivolumab for advanced renal cell carcinoma (RCC) that is unresponsive to nivolumab monotherapy
Year: 2018
Type: article
Abstract: Background: X4P-001 is an oral, selective, allosteric, CXCR4 inhibitor. In melanoma patients (pts), single agent X4P-001 increased tumor inflammatory signature and antigen presentation/processing gene expression scores in the tumor microenvironment (TME) and promoted activated, cytotoxic T cell infiltration. It is hypothesized that X4P-001 has the ability to restore immunity within the TME and potentially enhance the antitumor activity of checkpoint inhibitors.
Source: Annals of Oncology
Authors: T.K. Choueiri, M.B. Atkins, T.L. Rose, R.S. Alter, E. Tsiroyannis, K. Niland, Y. Wang, S. Parasuraman, L. Gan, D.F. McDermott
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $5,080
OpenAlex ID: W2898130261